Report cover image

Global Drugs Based on Gene Therapy Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 193 Pages
SKU # APRC20360116

Description

Summary

According to APO Research, the global Drugs Based on Gene Therapy market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Drugs Based on Gene Therapy market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Drugs Based on Gene Therapy is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Drugs Based on Gene Therapy market include Akcea Therapeutics, Alnylam Pharmaceuticals, AnGes, Biogen, Bluebird bio, Gilead Sciences, Human Stem Cells Institute, Orchard Therapeutics and Sarepta Therapeutics, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Drugs Based on Gene Therapy, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Drugs Based on Gene Therapy, also provides the value of main regions and countries. Of the upcoming market potential for Drugs Based on Gene Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drugs Based on Gene Therapy revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Drugs Based on Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Drugs Based on Gene Therapy company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Drugs Based on Gene Therapy Segment by Company

Akcea Therapeutics
Alnylam Pharmaceuticals
AnGes
Biogen
Bluebird bio
Gilead Sciences
Human Stem Cells Institute
Orchard Therapeutics
Sarepta Therapeutics
SIBIONO
Spark Therapeutics
Sunway Biotech
Amgen
Novartis
Drugs Based on Gene Therapy Segment by Type

Viral Gene Therapy
Non-viral Gene Therapy
Drugs Based on Gene Therapy Segment by Application

Neurological Diseases
Cancer
Other
Drugs Based on Gene Therapy Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Drugs Based on Gene Therapy status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Drugs Based on Gene Therapy key companies, revenue, market share, and recent developments.
3. To split the Drugs Based on Gene Therapy breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Drugs Based on Gene Therapy market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Drugs Based on Gene Therapy significant trends, drivers, influence factors in global and regions.
6. To analyze Drugs Based on Gene Therapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs Based on Gene Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Drugs Based on Gene Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs Based on Gene Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs Based on Gene Therapy industry.
Chapter 3: Detailed analysis of Drugs Based on Gene Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Drugs Based on Gene Therapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Drugs Based on Gene Therapy in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Table of Contents

193 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Drugs Based on Gene Therapy Market Size, 2020 VS 2024 VS 2031
1.3 Global Drugs Based on Gene Therapy Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Drugs Based on Gene Therapy Market Dynamics
2.1 Drugs Based on Gene Therapy Industry Trends
2.2 Drugs Based on Gene Therapy Industry Drivers
2.3 Drugs Based on Gene Therapy Industry Opportunities and Challenges
2.4 Drugs Based on Gene Therapy Industry Restraints
3 Drugs Based on Gene Therapy Market by Company
3.1 Global Drugs Based on Gene Therapy Company Revenue Ranking in 2024
3.2 Global Drugs Based on Gene Therapy Revenue by Company (2020-2025)
3.3 Global Drugs Based on Gene Therapy Company Ranking (2023-2025)
3.4 Global Drugs Based on Gene Therapy Company Manufacturing Base and Headquarters
3.5 Global Drugs Based on Gene Therapy Company Product Type and Application
3.6 Global Drugs Based on Gene Therapy Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Drugs Based on Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Drugs Based on Gene Therapy Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Drugs Based on Gene Therapy Market by Type
4.1 Drugs Based on Gene Therapy Type Introduction
4.1.1 Viral Gene Therapy
4.1.2 Non-viral Gene Therapy
4.2 Global Drugs Based on Gene Therapy Sales Value by Type
4.2.1 Global Drugs Based on Gene Therapy Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Drugs Based on Gene Therapy Sales Value by Type (2020-2031)
4.2.3 Global Drugs Based on Gene Therapy Sales Value Share by Type (2020-2031)
5 Drugs Based on Gene Therapy Market by Application
5.1 Drugs Based on Gene Therapy Application Introduction
5.1.1 Neurological Diseases
5.1.2 Cancer
5.1.3 Other
5.2 Global Drugs Based on Gene Therapy Sales Value by Application
5.2.1 Global Drugs Based on Gene Therapy Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Drugs Based on Gene Therapy Sales Value by Application (2020-2031)
5.2.3 Global Drugs Based on Gene Therapy Sales Value Share by Application (2020-2031)
6 Drugs Based on Gene Therapy Regional Value Analysis
6.1 Global Drugs Based on Gene Therapy Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Drugs Based on Gene Therapy Sales Value by Region (2020-2031)
6.2.1 Global Drugs Based on Gene Therapy Sales Value by Region: 2020-2025
6.2.2 Global Drugs Based on Gene Therapy Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Drugs Based on Gene Therapy Sales Value (2020-2031)
6.3.2 North America Drugs Based on Gene Therapy Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Drugs Based on Gene Therapy Sales Value (2020-2031)
6.4.2 Europe Drugs Based on Gene Therapy Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Drugs Based on Gene Therapy Sales Value (2020-2031)
6.5.2 Asia-Pacific Drugs Based on Gene Therapy Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Drugs Based on Gene Therapy Sales Value (2020-2031)
6.6.2 South America Drugs Based on Gene Therapy Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Drugs Based on Gene Therapy Sales Value (2020-2031)
6.7.2 Middle East & Africa Drugs Based on Gene Therapy Sales Value Share by Country, 2024 VS 2031
7 Drugs Based on Gene Therapy Country-level Value Analysis
7.1 Global Drugs Based on Gene Therapy Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Drugs Based on Gene Therapy Sales Value by Country (2020-2031)
7.2.1 Global Drugs Based on Gene Therapy Sales Value by Country (2020-2025)
7.2.2 Global Drugs Based on Gene Therapy Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.3.2 USA Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.4.2 Canada Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.6.2 Germany Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.7.2 France Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.7.3 France Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.9.2 Italy Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.10.2 Spain Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.11.2 Russia Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.14.2 China Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.14.3 China Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.15.2 Japan Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.17.2 India Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.17.3 India Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.18.2 Australia Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.22.2 Chile Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.24.2 Peru Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.26.2 Israel Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.27.2 UAE Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.29.2 Iran Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Drugs Based on Gene Therapy Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Drugs Based on Gene Therapy Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Drugs Based on Gene Therapy Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Akcea Therapeutics
8.1.1 Akcea Therapeutics Comapny Information
8.1.2 Akcea Therapeutics Business Overview
8.1.3 Akcea Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.1.4 Akcea Therapeutics Drugs Based on Gene Therapy Product Portfolio
8.1.5 Akcea Therapeutics Recent Developments
8.2 Alnylam Pharmaceuticals
8.2.1 Alnylam Pharmaceuticals Comapny Information
8.2.2 Alnylam Pharmaceuticals Business Overview
8.2.3 Alnylam Pharmaceuticals Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.2.4 Alnylam Pharmaceuticals Drugs Based on Gene Therapy Product Portfolio
8.2.5 Alnylam Pharmaceuticals Recent Developments
8.3 AnGes
8.3.1 AnGes Comapny Information
8.3.2 AnGes Business Overview
8.3.3 AnGes Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.3.4 AnGes Drugs Based on Gene Therapy Product Portfolio
8.3.5 AnGes Recent Developments
8.4 Biogen
8.4.1 Biogen Comapny Information
8.4.2 Biogen Business Overview
8.4.3 Biogen Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.4.4 Biogen Drugs Based on Gene Therapy Product Portfolio
8.4.5 Biogen Recent Developments
8.5 Bluebird bio
8.5.1 Bluebird bio Comapny Information
8.5.2 Bluebird bio Business Overview
8.5.3 Bluebird bio Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.5.4 Bluebird bio Drugs Based on Gene Therapy Product Portfolio
8.5.5 Bluebird bio Recent Developments
8.6 Gilead Sciences
8.6.1 Gilead Sciences Comapny Information
8.6.2 Gilead Sciences Business Overview
8.6.3 Gilead Sciences Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.6.4 Gilead Sciences Drugs Based on Gene Therapy Product Portfolio
8.6.5 Gilead Sciences Recent Developments
8.7 Human Stem Cells Institute
8.7.1 Human Stem Cells Institute Comapny Information
8.7.2 Human Stem Cells Institute Business Overview
8.7.3 Human Stem Cells Institute Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.7.4 Human Stem Cells Institute Drugs Based on Gene Therapy Product Portfolio
8.7.5 Human Stem Cells Institute Recent Developments
8.8 Orchard Therapeutics
8.8.1 Orchard Therapeutics Comapny Information
8.8.2 Orchard Therapeutics Business Overview
8.8.3 Orchard Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.8.4 Orchard Therapeutics Drugs Based on Gene Therapy Product Portfolio
8.8.5 Orchard Therapeutics Recent Developments
8.9 Sarepta Therapeutics
8.9.1 Sarepta Therapeutics Comapny Information
8.9.2 Sarepta Therapeutics Business Overview
8.9.3 Sarepta Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.9.4 Sarepta Therapeutics Drugs Based on Gene Therapy Product Portfolio
8.9.5 Sarepta Therapeutics Recent Developments
8.10 SIBIONO
8.10.1 SIBIONO Comapny Information
8.10.2 SIBIONO Business Overview
8.10.3 SIBIONO Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.10.4 SIBIONO Drugs Based on Gene Therapy Product Portfolio
8.10.5 SIBIONO Recent Developments
8.11 Spark Therapeutics
8.11.1 Spark Therapeutics Comapny Information
8.11.2 Spark Therapeutics Business Overview
8.11.3 Spark Therapeutics Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.11.4 Spark Therapeutics Drugs Based on Gene Therapy Product Portfolio
8.11.5 Spark Therapeutics Recent Developments
8.12 Sunway Biotech
8.12.1 Sunway Biotech Comapny Information
8.12.2 Sunway Biotech Business Overview
8.12.3 Sunway Biotech Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.12.4 Sunway Biotech Drugs Based on Gene Therapy Product Portfolio
8.12.5 Sunway Biotech Recent Developments
8.13 Amgen
8.13.1 Amgen Comapny Information
8.13.2 Amgen Business Overview
8.13.3 Amgen Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.13.4 Amgen Drugs Based on Gene Therapy Product Portfolio
8.13.5 Amgen Recent Developments
8.14 Novartis
8.14.1 Novartis Comapny Information
8.14.2 Novartis Business Overview
8.14.3 Novartis Drugs Based on Gene Therapy Revenue and Gross Margin (2020-2025)
8.14.4 Novartis Drugs Based on Gene Therapy Product Portfolio
8.14.5 Novartis Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.